Drug intelligence / Profile preview

XW020

Development stage: Preclinical
Lead developer: Sciwind Biosciences
Modality: Peptides
Administration: Subcutaneous

Overview

XW020 is a long-acting injectable peptide being developed by Hangzhou Sciwind Biosciences for the treatment of overweight and obesity. Currently in the discovery stage, XW020 is designed to address a significant limitation of existing weight-loss therapies—the loss of lean muscle mass. The drug acts through distinct, currently undisclosed mechanisms to promote body weight reduction while simultaneously helping to preserve muscle mass, potentially improving the overall metabolic profile and physical function of patients undergoing weight-loss treatment.

Beyond the preview

Go deeper on XW020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XW020.

Explore the full profile